Abbvie

This study tests a one-time gene therapy called surabgene lomparvovec (Sura-vec) for diabetic retinopathy, a common eye problem from diabetes that can lead to blindness. About 576 adults with moderate-to-severe non-proliferative diabetic retinopathy will receive either the gene t…

This study tests a drug called risankizumab in children with juvenile psoriatic arthritis, a condition causing joint pain and swelling. About 40 kids will receive either risankizumab or the standard drug adalimumab for 24 weeks, with responders continuing for up to 2 years. The g…

This study tests a new drug called etentamig against standard treatments for adults with multiple myeloma that has returned or stopped responding. About 380 participants will receive either etentamig or a standard therapy chosen by their doctor. The goal is to see if etentamig ca…

This study tests a new drug called telisotuzumab adizutecan (ABBV-400) combined with an immunotherapy drug (budigalimab or pembrolizumab) in people with advanced non-squamous lung cancer who have not had prior treatment. The goal is to find the best dose that is safe and effectiv…

This study tests an experimental drug called telisotuzumab adizutecan combined with standard chemotherapy in people whose colorectal cancer has spread. The goal is to see if the combination shrinks tumors and is safe. About 390 adults will take part at hospitals worldwide.

This study tests whether the drug ubrogepant can prevent menstrual migraines when taken daily for a week around each period. About 496 women with regular cycles and a history of menstrual migraines will receive either ubrogepant or a placebo for three cycles, then all may receive…

This Phase 3 study tests a new drug, telisotuzumab adizutecan, combined with bevacizumab, against the standard treatment (LONSURF plus bevacizumab) in 700 adults with advanced colorectal cancer that has stopped responding to prior therapies. The goal is to see if the new combo sh…

This large Phase 2/3 trial is testing whether adding an investigational drug called telisotuzumab adizutecan to standard chemotherapy (FOLFOX) can help people with metastatic pancreatic cancer live longer or shrink their tumors. About 900 participants will be randomly assigned to…

This study tests a new drug called ABBV-706 combined with the immunotherapy atezolizumab as a first treatment for people with extensive-stage small cell lung cancer, a fast-growing cancer that has spread. About 180 adults will receive either the new combination at one of two dose…

This phase 3 trial is testing atogepant, a daily pill already approved for adults, to prevent episodic migraines in children aged 6 to 17. About 450 participants will receive either a low or high dose of the drug or a placebo for 12 weeks. The goal is to see if it safely reduces …

This early-stage study tests a single dose of ABBV-519 in 30 adults with moderate lupus or rheumatoid arthritis. Researchers will check how the drug moves through the body, how it affects immune cells, and whether it is safe. Participants will be followed for about a year to moni…

This phase 2 trial is testing three different doses of an investigational drug called telisotuzumab vedotin in about 150 adults with a specific type of advanced lung cancer (non-small cell lung cancer that has high levels of a protein called c-Met and no EGFR mutation). The drug …

This phase 3 trial tests whether upadacitinib (Rinvoq) can help regrow hair in people with severe alopecia areata, an autoimmune condition that causes patchy or total hair loss. About 1500 adults and teens will receive either the drug or a placebo daily for up to 160 weeks. The m…

This study tests a gene therapy called ABBV-RGX-314 for people with wet age-related macular degeneration (AMD), a leading cause of vision loss. The goal is to see if a single treatment can reduce the need for frequent eye injections while keeping vision stable. About 561 adults a…

This study follows 700 adults with moderate-to-severe plaque psoriasis who are already prescribed risankizumab by their doctor. Researchers will track changes in quality of life, including skin symptoms and daily impacts, over up to 2.5 years. The goal is to see how well the drug…

This study tests a gel stent implant designed to lower eye pressure in people with glaucoma. About 130 adults aged 45 and older will receive the stent through one of two surgical methods. Researchers will check safety and how well the stent reduces eye pressure over 12 months.

This Phase 2 trial tests mirvetuximab soravtansine, a targeted drug, combined with standard chemotherapy (carboplatin) or bevacizumab in 400 people with a specific type of ovarian cancer (FRα-positive). The study aims to find the best dose and combination to shrink tumors and con…

This phase 2 trial is testing four different drugs—risankizumab, trosunilimab, lutikizumab, and ABBV-8736—in about 540 adults with moderate to severe Crohn's disease. The goal is to see if these targeted therapies can reduce inflammation and improve symptoms. Participants will re…

This study tests whether upadacitinib, an oral tablet, can help adults with moderate to severe eczema (atopic dermatitis) who didn't get enough relief from dupilumab injections. About 200 participants will be randomly assigned to take upadacitinib or continue dupilumab for 8 week…

This study tests an experimental drug called ABBV-1758 in about 210 people with Alzheimer's disease. The drug is given by IV or injection every 4 weeks for 24 weeks. Researchers are checking if it is safe and whether it can reduce amyloid plaques in the brain, a hallmark of Alzhe…

This phase 2 study tests an investigational drug called telisotuzumab adizutecan in about 100 people aged 12 and older with advanced solid tumors that have a specific genetic change (MET amplification). The drug is given through an IV and aims to shrink tumors or stop them from g…

This study tests upadacitinib (RINVOQ), a daily oral medication, in 110 children aged 2 to 18 with moderate to severe Crohn's disease who haven't improved with other treatments. The trial has three parts: an initial 12-week open-label phase, a 52-week double-blind maintenance pha…

This study follows 120 adults with advanced Parkinson's disease in Belgium who are prescribed a drug called Foslevodopa/Foscarbidopa. The drug is given as a continuous infusion under the skin to help control symptoms. Researchers will track how much 'off' time (when symptoms like…

This study is testing an experimental drug called surzetoclax, alone or combined with other cancer drugs, in about 130 adults with multiple myeloma that has returned or stopped responding to prior treatments. The goal is to find the safest dose and see if it can shrink or control…

This early-stage study tests a new drug called azirkitug, alone or with other cancer medicines, in people with advanced solid tumors like lung, head/neck, and pancreatic cancers. The goal is to find safe doses and check side effects. About 694 adults will take part worldwide, rec…

This phase 2 study tests two experimental drugs, lutikizumab and ravagalimab, alone or together, in about 180 adults with moderate-to-severe rheumatoid arthritis who have not improved with other treatments. The goal is to see if these drugs can reduce joint pain and swelling bett…

This study tracks 250 people with moderate-to-severe Crohn's disease who are switching to either upadacitinib or risankizumab after a first treatment didn't work well enough. Researchers will see if these drugs help patients achieve remission without needing steroids over 18 mont…

This phase 3 study tests the drug risankizumab in about 120 children aged 2 to 18 with moderate to severe ulcerative colitis. The trial has three parts: an initial 12-week IV treatment period, a 52-week maintenance phase where patients get one of two doses by injection, and a lon…

This early-stage trial tests an investigational drug called ABBV-901, alone or with a standard drug bevacizumab, in about 219 adults with advanced ovarian cancer that no longer responds to platinum chemotherapy. The main goals are to check safety and see if the drug can shrink tu…

This study looks at how well risankizumab works for people with moderate to severe ulcerative colitis in real-world settings. About 200 adults in Germany and Austria will take the drug as prescribed by their doctor and be followed for up to 52 weeks. The goal is to see if symptom…

This study tests whether giving the targeted drug mirvetuximab soravtansine together with standard chemotherapy (carboplatin) before surgery can shrink advanced ovarian, fallopian tube, or peritoneal cancers that have a specific protein (FRα). About 140 adults with stage III or I…

This study tests a new medicine called ABBV-6628 for people with geographic atrophy, an advanced form of dry age-related macular degeneration that causes vision loss. About 66 adults aged 50 and older will receive eye injections of the study drug or an approved treatment (SYFOVRE…

This study tests an experimental drug called etentamig combined with daratumumab in people newly diagnosed with multiple myeloma who are not eligible for a stem cell transplant. About 660 participants will receive either the new combination or standard treatment. The goal is to s…

This study tests whether an injection of gemibotulinumtoxinA (a botulinum toxin similar to Botox) can help surgeons close the belly wall during open ventral hernia repair without needing a complex additional procedure. About 200 adults with a midline ventral hernia will receive e…

This phase 3 trial compares a new targeted drug, telisotuzumab vedotin, to the standard chemotherapy docetaxel in adults with a specific type of advanced non-small cell lung cancer that has a high level of a protein called c-Met. About 698 participants worldwide will receive eith…

This early-stage study is testing an experimental drug called pivekimab sunirine in about 18 children whose acute myeloid leukemia (AML) has come back or not responded to standard treatments. The main goals are to check the drug's safety and how it moves through the body. Partici…

This study tests whether adding an experimental drug called telisotuzumab adizutecan to the standard targeted therapy osimertinib can improve outcomes for people with advanced EGFR-mutated non-small cell lung cancer. About 854 adults will be enrolled worldwide. The trial has two …

This study tests whether the drug atogepant (Qulipta) can safely prevent chronic migraines in teenagers aged 12 to 17. About 420 teens with chronic migraine will take either atogepant or a placebo pill daily for 12 weeks. Researchers will track side effects and changes in monthly…

This study tests an experimental drug called etentamig (ABBV-383) in about 210 adults whose multiple myeloma has come back or stopped responding to other treatments. The main goals are to find the best dose and check for side effects. Participants receive the drug as an infusion …

This study follows 400 adults with moderate to severe ulcerative colitis who are already prescribed upadacitinib (RINVOQ) by their doctor. Researchers will track how well the drug controls symptoms like diarrhea and rectal bleeding over two years. The goal is to see if early impr…

This study tests a device called ARTIA, a special tissue matrix used during implant-based breast reconstruction after mastectomy. About 264 adults who need immediate reconstruction will receive ARTIA to see if it reduces major complications like infection or implant failure. The …

This phase 2 trial tests whether the investigational drug telisotuzumab adizutecan can prevent colorectal cancer from coming back in patients who have no visible tumors but still have cancer DNA in their blood after surgery. About 140 adults will be randomly assigned to receive e…

This study tests an experimental drug called IMGN151, alone or with other cancer treatments, in about 377 adults with gynecologic cancers like ovarian cancer. The goal is to check safety and find the best dose. Participants get the drug through an IV and will have regular check-u…

This study tests a cancer pill called venetoclax in 14 Japanese adults with a rare blood cancer (Waldenström macroglobulinemia) that has come back or not responded to treatment. Participants take the drug by mouth daily, with doses slowly increased. The main goal is to see how ma…

This study tests risankizumab, a drug already used in adults, in children aged 2 to 18 with moderate to severe Crohn's disease. About 110 kids will receive the drug intravenously then by injection over several years. The goal is to see if it safely reduces symptoms and gut inflam…

This study looks at how well the drug combination Foslevodopa/Foscarbidopa works for people with early advanced Parkinson's disease in everyday German clinics. About 125 adults aged 18-64 who are already prescribed this drug will be followed for up to 12 months. Researchers will …

This study tests a drug called mirvetuximab soravtansine (MIRV) in people with ovarian, peritoneal, or fallopian tube cancer that no longer responds to platinum chemotherapy and has high levels of a protein called FRα. The drug delivers a cancer-killing agent directly to tumor ce…

This study tests a new oral medication, upadacitinib, in children aged 1 to 17 with active systemic juvenile idiopathic arthritis (sJIA), a rare and serious form of arthritis that can affect the whole body. About 90 participants will receive either upadacitinib or the standard in…

This Phase 2 trial tests whether a new drug called MEDI0618 can safely reduce the number of migraine headache days in adults with episodic migraine. About 488 participants will receive either the drug or a placebo as a shot under the skin. The main goal is to see if the drug lowe…

This early-stage trial tests an investigational drug called ABBV-319 in 36 adults with lupus or Sjogren's disease. The drug is designed to deplete overactive B cells, which are part of the immune system that cause inflammation and symptoms. Participants receive two doses by IV, 2…

This early-stage study tests the safety and tolerability of a new injectable drug called ABBV-295 in 48 adults with obesity. Participants will receive either the drug or a placebo over several weeks. Researchers will monitor side effects, changes in body weight, and how the drug …

This early-stage trial tests an investigational drug called ABBV-438 in about 127 adults with multiple myeloma that has come back or stopped responding to treatment. The study has two parts: first, finding a safe dose, then testing that dose in more people. The main goal is to ch…

This early-phase study tests an experimental drug called ABBV-711, alone or with another drug (budigalimab), in adults with advanced squamous tumors (like certain lung or head and neck cancers). The main goals are to check safety and see if the tumors shrink. About 220 people wil…

This study will follow about 1,000 adolescents and adults in China who are prescribed upadacitinib for moderate to severe atopic dermatitis (eczema). Researchers will track how patients use the medication, any dose changes, and how well they stick to their treatment over 12 month…

This study follows 270 Italian adults with advanced Parkinson's disease who are already prescribed Foslevodopa/Foscarbidopa, a drug given as a continuous infusion under the skin. Researchers will track how the drug affects quality of life over 12 months using a standard questionn…

This study tests an experimental drug called etentamig (ABBV-383) in adults with AL amyloidosis, a rare disease where abnormal proteins build up in organs. About 76 participants will receive the drug by infusion to see if it is safe and can control the disease. The trial has two …

This study tests a new combination of two drugs, etentamig and iberdomide, in adults with multiple myeloma that has returned or stopped responding to treatment. The goal is to find a safe dose and see if the combo can control the cancer. About 135 participants will take part at s…

This study tests a combination of two drugs, venetoclax and azacitidine, in about 100 adults in India with newly diagnosed acute myeloid leukemia (AML) who are not healthy enough for standard intensive chemotherapy. The goal is to see if the combo can put the cancer into remissio…

This study tests a one-time gene therapy called RGX-314 for wet age-related macular degeneration (AMD), a leading cause of vision loss. About 714 adults aged 50-89 who currently need regular eye injections will receive either the gene therapy or standard treatment. The goal is to…

This study follows 200 adults in Japan with moderate to severe ulcerative colitis who are already prescribed risankizumab by their doctor. Researchers will track how well the drug controls symptoms like diarrhea and rectal bleeding over up to 156 weeks. The goal is to see if the …

This phase 3 trial tests different ways to start venetoclax combined with obinutuzumab or acalabrutinib in 170 adults with untreated chronic lymphocytic leukemia (CLL). The goal is to find the safest ramp-up schedule to prevent tumor lysis syndrome, a dangerous side effect. Parti…

This study tests an experimental drug called ABBV-142 in people with idiopathic pulmonary fibrosis (IPF), a rare lung disease that causes scarring and breathing problems. About 165 adults will receive either ABBV-142 or a placebo for 52 weeks to see if the drug is safe and can he…

This study tests two medicines for children aged 2 to 12 with moderate to severe eczema that isn't controlled by creams. One group gets upadacitinib (a daily pill or liquid), the other gets dupilumab (an injection every 2 or 4 weeks). The goal is to see which better reduces skin …

This Phase 2 study tests a new drug, telisotuzumab adizutecan (ABBV-400), combined with standard chemotherapy and an immunotherapy drug for people with advanced stomach, gastroesophageal junction, or esophageal cancer that cannot be removed by surgery. About 180 adults will recei…

This early-stage trial tests an investigational drug called ABBV-324 in about 232 adults with liver cancer (hepatocellular carcinoma) or a type of lung cancer (squamous-cell non-small cell lung cancer). Some participants receive ABBV-324 alone, while others get a standard drug ca…

This study tests a new drug, telisotuzumab adizutecan, in people with advanced EGFR-mutated non-small cell lung cancer whose cancer has progressed after a third-generation targeted therapy. About 430 adults will receive either the new drug or standard care. The goal is to see if …

This study tests a daily pill called upadacitinib for people with moderate to severe hidradenitis suppurativa (HS), a painful skin condition causing boils in the armpits, groin, and genital area. The trial includes about 1,328 adults and teens who have not improved with standard …

This study tests whether two experimental drugs (livmoniplimab and budigalimab) combined with chemotherapy work better than the current standard treatment (pembrolizumab plus chemo) for people with untreated metastatic non-squamous non-small cell lung cancer. About 840 adults wil…

This study follows about 240 people in Japan with moderate to severe Crohn's disease who are taking upadacitinib, an approved drug. Researchers will track side effects and how well the drug controls the disease over up to 64 weeks. The goal is to see how the drug works in everyda…

This study follows about 1,200 people with psoriatic arthritis to see how long they continue taking risankizumab or other advanced treatments in everyday clinical practice. Researchers will track treatment persistence over 24 months. The goal is to understand real-world effective…

This study tracks about 678 adults with moderate to severe rheumatoid arthritis in Germany to see how long they stay on either upadacitinib or TNF inhibitors. Doctors choose the treatment before the study starts, based on standard care. The goal is to learn which drug people stic…

This study tests an experimental drug, etentamig, in people with multiple myeloma, a blood cancer. The drug is given alone or with other cancer medicines. The goal is to see if it is safe and works against the cancer. About 440 adults will take part at sites worldwide.

This study follows about 700 adults with advanced diffuse large B-cell lymphoma or follicular lymphoma who are receiving epcoritamab as part of their routine care. Researchers will track how well the drug controls the cancer over up to 3 years. The goal is to see if results from …

This study tests whether giving a second course of venetoclax plus obinutuzumab can control chronic lymphocytic leukemia (CLL) when it comes back after initial treatment. About 75 adults whose CLL returned after prior successful therapy will receive the drug combination for up to…

This Phase 2 study tests an investigational drug called emraclidine in about 268 adults with schizophrenia. The trial has two parts: Part A looks at how the drug moves through the body and its safety at different doses, while Part B measures whether it improves symptoms like hall…

This program allows eligible people with Parkinson's disease to receive tavapadon, an experimental oral tablet, before it is officially approved. A doctor must decide if the potential benefit outweighs the risks. The program is only available in certain territories and for those …

This program offers early access to telisotuzumab adizutecan for people with solid tumors who have no other suitable treatment options and cannot join a clinical trial. A doctor must decide if the potential benefit outweighs the risks. The drug is not yet approved by local regula…

This program offers early access to venetoclax, a targeted cancer pill, for people with certain blood cancers like leukemia or lymphoma who have no other good treatment options. A doctor must decide if the potential benefit outweighs the risks. The drug is not yet approved in all…

This program offers early access to upadacitinib (Rinvoq) for people with Crohn's disease, ulcerative colitis, certain types of arthritis, or atopic dermatitis who have no other suitable treatments and cannot join ongoing clinical trials. A doctor must decide if the potential ben…

This program provides early access to the investigational drug ABBV-706 for people with small cell lung cancer who have no other treatment options and cannot join a clinical trial. A doctor must decide if the potential benefit outweighs the risks. The drug is given by intravenous…

This early-stage trial is testing a new drug called ABBV-291 in adults with Non-Hodgkin's lymphoma that has come back or stopped responding to treatment. The study will first find the safest dose, then check if the drug can shrink tumors. About 165 participants will take part wor…

This early-stage trial tests an investigational drug called ABBV-319 in about 154 adults with certain B-cell cancers (diffuse large B-cell lymphoma, follicular lymphoma, or chronic lymphocytic leukemia) that have returned or not responded to standard treatments. The study has two…

This large study compares Armour Thyroid, a natural thyroid extract, to standard synthetic T4 (levothyroxine) in adults with primary hypothyroidism. About 2,800 participants who are stable on synthetic T4 will be randomly assigned to continue their current treatment or switch to …

This study tests a daily pill called upadacitinib for people with severe alopecia areata, an immune system attack on hair follicles causing at least 25% scalp hair loss. About 123 teens and adults in Japan will take either the drug or a placebo for up to 104 weeks to see if it sa…

This phase 2 trial tests the drug venetoclax (a pill) in 110 people with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The study includes two groups: those with a specific genetic change (17p deletion) and those who have failed oth…

This study tests two injectable drugs, lutikizumab and risankizumab, alone or together, in 120 adults with active psoriatic arthritis. The goal is to see if they can reduce joint pain, swelling, and other symptoms. Participants will be randomly assigned to one of three treatment …

This study follows 80 Chinese adults with moderate to severe ulcerative colitis who are already prescribed upadacitinib by their doctor. Researchers will collect routine medical data over one year to see if the drug improves symptoms like bloody diarrhea. No extra tests or visits…

This study looks at the safety and effectiveness of atogepant, a drug already approved for migraine prevention, in Korean adults. About 3000 people with chronic or episodic migraines will take the drug as prescribed by their doctor and be followed for up to 12 weeks. The goal is …

This study tests an investigational drug called gemibotulinumtoxinA (a type of botulinum toxin) injected into arm muscles to reduce tremor in adults with essential tremor. About 94 participants will receive either the drug or a placebo injection. Researchers will measure changes …

This study tests whether cariprazine (Vraylar) can safely ease depressive episodes in teens aged 10-17 with bipolar I disorder. Around 380 participants will receive either the drug or a placebo for 6 weeks, with dose adjustments based on response. The goal is to see if the drug i…

This study looks at whether a new pump-delivered medication (Foslevodopa/Foscarbidopa) can help improve sleep problems in people with advanced Parkinson's disease. About 103 adults in Spain will take part, and researchers will track their sleep quality over 12 weeks using a simpl…

This study tests a new drug called ABBV-932 for adults with generalized anxiety disorder (GAD) who still have symptoms despite taking antidepressants. About 315 participants will receive either ABBV-932 or a placebo alongside their current antidepressant for 6 weeks. The goal is …

This study is testing the safety and tolerability of an experimental drug called ABBV-932 for people with bipolar I or II disorder who are currently in a depressive episode. About 200 adults will take the drug as capsules for 26 weeks, with regular check-ups and tests to monitor …

This study tests a new injectable gel called NOA VOLUME against the well-known JUVÉDERM VOLUMA XC for improving mid-face volume loss. About 231 adults with moderate to severe cheek hollowing will receive injections, with optional touch-ups. The goal is to see if NOA VOLUME is as …

This study tests an experimental drug, icalcaprant, for adults with major depressive disorder who are currently having a depressive episode. About 195 participants will take either the drug or a placebo daily for 6 weeks. Researchers will measure changes in depression symptoms an…

This phase 2 trial tests whether different eye drops can prevent or reduce eye problems caused by the cancer drug mirvetuximab soravtansine in 100 people with recurrent ovarian cancer. Participants will receive the cancer drug along with either lubricating drops, steroid drops, o…

This study tests an oral medication called ubrogepant, already approved for adults, to see if it safely and effectively treats migraine attacks in children and adolescents aged 6 to 17. About 1,059 participants with a history of migraine will receive either a low or high dose of …

This study tests an experimental drug called icalcaprant for treating depression in people with bipolar I or II disorder. About 195 adults will take either the drug or a placebo daily for 6 weeks. Researchers will measure changes in depression symptoms and watch for side effects.

This early-stage study is testing a new drug called ABBV-295 in 24 healthy Japanese adults who are overweight or obese. The main goal is to check the drug's safety and how the body processes it. Participants receive injections of the drug or a placebo, and researchers monitor for…

This study looks at whether taking ubrogepant (a migraine medication) during the earliest phase of a migraine—called the prodrome—can prevent moderate to severe headache pain. About 189 adults who already use ubrogepant will take it as usual and report their symptoms over 13 week…

This study tests an injectable gel called ELAPR002f to see if it safely reduces atrophic acne scars (indented scars) on the cheeks. About 395 adults with moderate to severe scarring will receive either the gel or a saline placebo over 2 months, then be followed for a year. The go…

This study is testing the drug eluxadoline (Viberzi) in children aged 6 to 17 who have irritable bowel syndrome with diarrhea (IBS-D). The goal is to see if it improves stool consistency and is safe for kids. About 95 children will take either the drug or a placebo for 4 weeks, a…

This early-phase study will enroll 60 healthy volunteers to compare how the drug risankizumab behaves in the body when given as a shot under the skin versus through an IV. The main goals are to measure side effects and drug levels in the blood. No treatment or health benefit is e…

This early-stage trial is testing a new drug called ABBV-313 in healthy adult volunteers. The main goal is to check if the drug is safe and how the body handles it, including how it is absorbed and broken down. Participants receive either the drug or a placebo as an injection or …

This early-stage trial is testing a single dose of bretisilocin in 26 healthy adults from Japanese, Han Chinese, and Non-Asian backgrounds. Researchers are checking for side effects and how the drug moves through the body. The goal is to gather basic safety information before tes…

This early-stage study tests a single dose of ABBV-547 in healthy adults to check its safety, how the body processes it, and any side effects. About 121 participants in the US and Japan will receive either the drug or a placebo. The study has two parts with different dosing group…

This study looks at how the body absorbs different versions of the drug emraclidine in 12 healthy adults. Participants take a single dose of each version and have their blood tested. The goal is to compare the drug levels and check for side effects, not to treat any disease.

This early-stage study is testing a new drug called ABBV-1451 in healthy adults to see how safe it is and how the body processes it. About 90 volunteers will receive a single dose, and researchers will monitor for side effects and measure drug levels in the blood. The study also …

This study looks at how taking itraconazole (a common antifungal) changes the way the body processes an experimental drug called ABBV-722. It involves 12 healthy adults and focuses on safety and drug levels in the blood. The goal is to gather information, not to treat any disease…

This early-stage study is testing an experimental drug called emraclidine in 40 healthy adults aged 65 and older. Researchers want to see how the drug moves through the body and whether it causes any side effects. Participants will receive either emraclidine or a placebo pill. Th…

This early-stage study is testing whether a new drug called ABBV-722 changes how the body processes several common medications. Twelve healthy adults will take ABBV-722 along with a 'cocktail' of other drugs (midazolam, digoxin, pitavastatin, metformin, and sitagliptin) to see if…

This Phase 1 study tests how two oral drugs, ABBV-722 and upadacitinib, affect each other in the body. Thirty-two healthy adults will take multiple doses to measure drug levels and check for side effects. The goal is to understand safety and drug interactions, not to treat any di…

This study looks back at medical records of 2,000 people with hepatitis C who took an 8-week course of glecaprevir/pibrentasvir (G/P). The goal is to see how safe and effective the treatment is for those also taking prescription or illegal drugs. Researchers will track side effec…

This study observes how doctors use a treat-to-target strategy for people with Crohn's disease or ulcerative colitis in routine care. Researchers will review medical records of 2000 adults over 24 months to see if adjusting treatment based on disease activity improves outcomes. N…

This study aims to understand how alopecia areata, vitiligo, and hidradenitis suppurativa affect the quality of life and daily functioning of teenagers and adults. Researchers will collect information from nearly 2,800 participants across multiple countries using surveys and skin…

This early-stage study is testing a new drug called ABBV-243 in healthy adults to see if it is safe and how the body processes it. About 66 participants will receive either the drug or a placebo, given as an injection or IV. The study does not aim to treat any disease, but to gat…

This observational study tracks the safety of Ubrelvy and Qulipta, two migraine drugs, when used during pregnancy. Researchers will follow about 1,884 pregnant women with migraine in the US and Canada, comparing those who take either drug to a group who does not. The goal is to s…

This study is tracking 500 people with chronic lymphocytic leukemia (CLL) who are taking venetoclax, either alone or with other drugs, as part of their normal care in Austria, Germany, and Switzerland. Researchers want to see how well the treatment works in real-life settings and…

This early-stage study is testing a new drug called ABBV-1042 in 48 healthy adults to see if it is safe and how the body processes it. Participants will receive either the drug or a placebo and be monitored for side effects, vital signs, and lab changes. This study does not aim t…